ClinicalTrials.gg

Lymphoma, B-Cell clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 886 studies for Lymphoma, B-Cell across more than 10 countries. 286 are recruiting or about to start. 540 of them are mainly about Lymphoma, B-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 5 narrower conditions too, such as Lymphoma, Large B-Cell, Diffuse: 3,251 studies, 791 open.

ClinicalTrials.gov finds 4,727 studies for Lymphoma, B-Cell. How that becomes 885 here

This page counts the studies the registry files under Lymphoma, B-Cell, and those it files under no condition that list Lymphoma, B-Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 4,727Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2,350Filed under a narrower condition, counted on its own pageLymphoma, Large B-Cell, Diffuse 1,673 · Burkitt Lymphoma 361 · Lymphoma, B-Cell, Marginal Zone 260 · Lymphoma, AIDS-Related 20 · Lymphomatoid Granulomatosis 2
  3. −146List Lymphoma, B-Cell as a condition, but the registry did not file them under itMost often written as “DLBCL - Diffuse Large B Cell Lymphoma” (36), “Large B-cell Lymphoma” (14), and “Non-hodgkin Lymphoma,B Cell” (8). The registry filed them under other conditions only, most often Dendritic Cell Sarcoma, Interdigitating (43) and Recurrence (35).
  4. −1,346Match it another way182 name it in the title, 19 in a keyword, and 1,145 by a synonym or other text the search reads.
  5. 885The count on this page105 of them list Lymphoma, B-Cell in their own words; the registry filed them under no condition.

Status

Completed
256
Recruiting
208
Status unknown
111
Active, not recruiting
93
Terminated
92
Not yet recruiting
71

Phase

Phase 1
458
Phase 2
387
Phase 3
42
Early Phase 1
42
Phase 4
11

Where

United States
398
China
283
France
94
Italy
65
United Kingdom
64
Australia
63

Who develops what

Add Lymphoma, B-Cell to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 43 programs from 28 companies, 28 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Beijing Biotech, AstraZeneca and Daiichi Sankyo here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CyclophosphamideRecent, repeated
Evidence
  • NCT07911553 · AstraZeneca · Phase 3 · live · background · “Cyclophosphamide” · registered Oct 2026
  • NCT07569965 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Cyclophosphamide” · registered Apr 2026
  • NCT06564038 · AstraZeneca · Phase 2 · live · background · “Cyclophosphamide” · registered Aug 2024
  • NCT06047080 · Hoffmann-La Roche · Phase 3 · live · background · “Cyclophosphamide” · registered Sep 2023
  • NCT05972720 · CARGO Therapeutics · Phase 2 · background · “Cyclophosphamide Monohydrate (Conditional therapy)” · registered Jul 2023
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed78 studies
RituximabRecent, repeated
Evidence
  • NCT07911553 · AstraZeneca · Phase 3 · live · background · “Rituximab” · registered Oct 2026
  • NCT07520006 · Nurix Therapeutics, Inc. · Phase 2 · live · background · “rituximab” · registered Apr 2026
  • NCT07477366 · ImmunityBio, Inc. · Phase 2 · live · background · “rituximab” · registered Mar 2026
  • NCT06564038 · AstraZeneca · Phase 2 · live · background · “Rituximab” · registered Aug 2024
  • NCT06230224 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Rituximab” · registered Dec 2023
Hoffmann-La Roche45% of its industry studiesUS: Hoffmann-La Roche (FDA 1997) + 3 othersEU: Hoffmann-La Roche (EMA 1998) + 6 others67 studies
DoxorubicinRecent, repeated
Evidence
  • NCT07911553 · AstraZeneca · Phase 3 · live · background · “Doxorubicin” · registered Oct 2026
  • NCT06564038 · AstraZeneca · Phase 2 · live · background · “Doxorubicin” · registered Aug 2024
  • NCT06047080 · Hoffmann-La Roche · Phase 3 · live · background · “Doxorubicin” · registered Sep 2023
  • NCT05605899 · Gilead Sciences · Phase 3 · live · comparator · “Doxorubicin” · registered Oct 2022
  • NCT05201248 · Genmab · Phase 2 · live · background · “Doxorubicin” · registered Jan 2022
Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed45 studies
PrednisoneRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07911553 · AstraZeneca · Phase 3 · live · background · “Prednisone” · registered Oct 2026
  • NCT06564038 · AstraZeneca · Phase 2 · live · background · “Prednisone (or equivalent)” · registered Aug 2024
  • NCT06047080 · Hoffmann-La Roche · Phase 3 · live · background · “Prednisone” · registered Sep 2023
  • NCT05605899 · Gilead Sciences · Phase 3 · live · comparator · “Prednisone” · registered Oct 2022
  • NCT05201248 · Genmab · Phase 2 · live · background · “Prednisone” · registered Jan 2022
Johnson & Johnson11% of its industry studies45 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07569965 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Fludarabine” · registered Apr 2026
  • NCT05972720 · CARGO Therapeutics · Phase 2 · background · “Fludarabine (Conditional therapy)” · registered Jul 2023
  • NCT05826535 · Lyell Immunopharma, Inc. · Phase 2 · live · background · “Fludarabine” · registered Mar 2023
  • NCT05605899 · Gilead Sciences · Phase 3 · live · background · “Fludarabine” · registered Oct 2022
  • NCT04989803 · Gilead Sciences · Phase 2 · live · background · “Fludarabine” · registered Jul 2021
Beijing Biotech18% of its industry studies44 studies
VincristineRecent, repeated
Evidence
  • NCT07911553 · AstraZeneca · Phase 3 · live · background · “Vincristine” · registered Oct 2026
  • NCT06564038 · AstraZeneca · Phase 2 · live · background · “Vincristine” · registered Aug 2024
  • NCT05605899 · Gilead Sciences · Phase 3 · live · comparator · “Vincristine” · registered Oct 2022
  • NCT05201248 · Genmab · Phase 2 · live · background · “Vincristine” · registered Jan 2022
  • NCT04529772 · AstraZeneca · Phase 3 · live · background · “Vincristine” · registered Aug 2020
Bristol-Myers Squibb9% of its industry studies34 studies
EtoposideRecent, repeated
Evidence
  • NCT06230224 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Etoposide” · registered Dec 2023
  • NCT05605899 · Gilead Sciences · Phase 3 · live · comparator · “Etoposide” · registered Oct 2022
  • NCT02592876 · Pfizer · Phase 2 · background · “etoposide” · registered Oct 2015
Hoffmann-La Roche14% of its industry studiesUS: off-patent, 5 generics marketed22 studies
obinutuzumabRecent, repeated
Evidence
  • NCT07520006 · Nurix Therapeutics, Inc. · Phase 2 · live · background · “obinutuzumab” · registered Apr 2026
  • NCT06634589 · BeOne Medicines · Phase 2 · live · background · “Obinutuzumab” · registered Oct 2024
Hoffmann-La Roche76% of its industry studiesUS: Hoffmann-La Roche (FDA 2013)EU: Hoffmann-La Roche (EMA 2014)22 studies

17 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
pirtobrutinibApproved: US 2023 · EU 2023☆ Track5 live phase-3 studies: NCT05023980, NCT04662255, NCT05254743Eli Lilly and Company
bexobrutideg☆ Track1 live phase-3 study: NCT07516093Nurix Therapeutics, Inc.
pirtobrutinibApproved: US 2023 · EU 2023☆ Track1 live phase-3 study: NCT07516093Nurix Therapeutics, Inc.
rondecabtagene autoleucel☆ Track1 live phase-3 study: NCT07188558Lyell Immunopharma, Inc.
surovatamig☆ Track2 live phase-3 studies: NCT07911553, NCT07215585AstraZeneca

The 5 in phase 3 with the nearest primary completion, of 43 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.zamtocabtagene autoleucel · Miltenyi Biomedicine GmbH · Phase 2 named, not the main aimstudied with Cyclophosphamidestudied with fludarabinestudied with bendamustineNCT04792489 DALY II USA/ MB-CART2019.1 for DLBCL — primary endpoint: Objective Response Rate · 315 enrolled
  • 14 Mar 2027 est.Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module, Autologous BCMA/CD38 dual-target CAR-T module, Autologous BCMA/GPRC5D dual-target CAR-T, Autologous CD33/CD123 dual-target CAR-T module, Autologous CD33/CLL1 dual-target CAR-T module, Autologous CD5/CD7 dual-target CAR-T module · Beijing Biotech · Phase 2 registry mapping onlyNCT07523555 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies — primary endpoint: Incidence of dose-limiting toxicities (DLTs) by module and dose level · 96 enrolled
  • 25 May 2027 est.CD19 t-haNK- IV Administration · ImmunityBio, Inc. · Phase 2 main aimNCT07125872 Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma — primary endpoint: Primary Endpoints( Efficacy) · 20 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lymphoma, B-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 10 open · Tyrosine kinase inhibitors (TKIs) 7 open · Antimetabolites 6 open · Antibody-drug conjugates (ADCs) 4 open · Immune checkpoint inhibitors 3 open

Coming up

111studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger. 37 (18%) take children under 18. 1 (<1%) are for women only and 0 (0%) for men only; 3 (1%) take healthy volunteers.

Recruiting studies that take each age, of 208
AgeWomenMen
1025 (12%)25 (12%)
18198 (95%)197 (95%)
30199 (96%)198 (95%)
40196 (94%)195 (94%)
50196 (94%)195 (94%)
65199 (96%)198 (95%)
75189 (91%)188 (90%)
85136 (65%)135 (65%)

Across all 886 studies, recruiting or not: 30% stop at 75 or younger and 7% at 65; 15% take children; <1% are for women only and <1% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, B-Cell studies take

Of 207 phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 151 mo37–78 · 207 studies47 mo37–81 · 90 studies54 mo37–75 · 117 studies
Phase 1/271 mo55–96 · 94 studies—64 mo45–82 · 52 studies
Phase 253 mo34–73 · 120 studies—61 mo37–81 · 94 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting1

Studies

Recruiting first, then most recently updated. Showing 50 of 886. Browse all 886 → or search them.